EP3681508A4 - Méthode et composition pour le traitement d'une infection virale - Google Patents
Méthode et composition pour le traitement d'une infection virale Download PDFInfo
- Publication number
- EP3681508A4 EP3681508A4 EP18857189.7A EP18857189A EP3681508A4 EP 3681508 A4 EP3681508 A4 EP 3681508A4 EP 18857189 A EP18857189 A EP 18857189A EP 3681508 A4 EP3681508 A4 EP 3681508A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- viral infection
- treating viral
- treating
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/051553 WO2018053123A1 (fr) | 2016-09-14 | 2017-09-14 | Méthodes et compositions de traitement d'infections virales |
US201862698365P | 2018-07-16 | 2018-07-16 | |
PCT/US2018/042226 WO2019055119A1 (fr) | 2017-09-14 | 2018-07-16 | Méthode et composition pour le traitement d'une infection virale |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3681508A1 EP3681508A1 (fr) | 2020-07-22 |
EP3681508A4 true EP3681508A4 (fr) | 2021-05-19 |
Family
ID=65723839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18857189.7A Pending EP3681508A4 (fr) | 2017-09-14 | 2018-07-16 | Méthode et composition pour le traitement d'une infection virale |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3681508A4 (fr) |
JP (3) | JP6820450B2 (fr) |
KR (2) | KR102295179B1 (fr) |
AU (2) | AU2018334386B2 (fr) |
CA (1) | CA3075729A1 (fr) |
IL (2) | IL285232B (fr) |
MX (1) | MX2020002883A (fr) |
RU (1) | RU2020113341A (fr) |
WO (1) | WO2019055119A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114209711A (zh) * | 2020-03-31 | 2022-03-22 | 菲尼克斯生物技术公司 | 用于治疗冠状病毒感染的方法和组合物 |
US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
KR20220151038A (ko) * | 2020-03-31 | 2022-11-11 | 피닉스 바이오테크놀러지 인코포레이티드. | 코로나바이러스 감염 예방를 위한 조성물 |
EP4009981B1 (fr) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Méthode et compositions pour le traitement d'une infection à coronavirus |
FR3109297A1 (fr) * | 2020-04-19 | 2021-10-22 | Ephyla | « Nouvel inhibiteur non protéique de furine » |
WO2022094816A1 (fr) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Formulation solide |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN165073B (fr) | 1986-05-13 | 1989-08-12 | Ziya Ozel Huseyin | |
US5236132A (en) | 1992-01-03 | 1993-08-17 | Vortec, Inc. | Gradient-force comminuter/dehydrator apparatus and method |
US5598979A (en) | 1995-04-20 | 1997-02-04 | Vortec, Inc. | Closed loop gradient force comminuting and dehydrating system |
CA2191923C (fr) | 1996-12-03 | 2000-10-24 | Ji-Won Yoon | Portulaca oleracea et croissance des cellules tumorales |
CN1307473A (zh) | 1998-05-19 | 2001-08-08 | 研究发展基金会 | 三萜组合物和它们的使用方法 |
CA2354037A1 (fr) | 1998-09-24 | 2000-03-30 | Ozelle Pharmaceuticals, Inc. | Extrait d'une espece de laurier-rose, composition pharmaceutique et procedes de preparation associes |
US6517015B2 (en) | 2000-03-21 | 2003-02-11 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
EP1309605A1 (fr) | 2000-08-18 | 2003-05-14 | The Board Of Trustees Of The University Of Illinois | Promedicaments de derives de l'acide betulinique pour le traitement du cancer et du vih |
US9931316B2 (en) * | 2004-01-06 | 2018-04-03 | Paul Edward Stamets | Antiviral activity from medicinal mushrooms and their active constituents |
US6715705B2 (en) | 2001-03-16 | 2004-04-06 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
ATE295087T1 (de) | 2001-04-09 | 2005-05-15 | Loders Croklaan Bv | Konzentrat von triterpenen |
WO2002091858A1 (fr) | 2001-05-11 | 2002-11-21 | University Of Ottawa | Compositions anxiolytiques de marcgraviaceae contenant de l'acide betulinique ou des derives d'acide betulinique et procedes associes |
US20040082521A1 (en) | 2002-03-29 | 2004-04-29 | Azaya Therapeutics Inc. | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases |
CA2487732C (fr) * | 2002-05-28 | 2013-10-15 | Bette Pollard | Utilisation de glucosides cardiotoniques pour le traitement de la mucovicidose et autres troubles dependant de il-8 |
AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
US20050026849A1 (en) | 2003-03-28 | 2005-02-03 | Singh Chandra U. | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
US20050239748A1 (en) | 2004-03-17 | 2005-10-27 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
US7118508B2 (en) | 2004-07-28 | 2006-10-10 | General Motors Corporation | Planetary transmissions having three interconnected gear members and clutched input members |
BRPI0519948A2 (pt) | 2005-02-09 | 2009-12-01 | Dabur Pharma Ltd | composto, processo para a preparação de um composto, composição farmacêutica e método de tratamento de cáncer em um mamìfero |
CA2603124A1 (fr) | 2005-03-29 | 2006-10-05 | Regents Of The University Of Minnesota | Oxydation selective des triterpenes a l'aide de tempo |
US20060252733A1 (en) | 2005-04-07 | 2006-11-09 | Novelix Pharmaceuticals, Inc. | Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism |
WO2006133314A2 (fr) | 2005-06-08 | 2006-12-14 | Regents Of The University Of Minnesota | Synthese d'aldehydes betuloniques et betuliniques |
CA2611435C (fr) | 2005-06-10 | 2013-01-08 | Pola Chemical Industries Inc. | Nouveau derive d'acide triterpenique et preparation comprenant celui-ci pour une application externe sur la peau |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
CN101374527A (zh) | 2005-12-16 | 2009-02-25 | 帕纳克斯医药公司 | 3-o-(3’,3’-二甲基琥珀酰基)桦木酸的药物盐的制备方法 |
EP1803461A1 (fr) * | 2005-12-27 | 2007-07-04 | Heinz-Herbert Fiebig | Utilisation therapeutique d'un extrait de feuilles de Nerium oleander |
GB0604535D0 (en) | 2006-03-07 | 2006-04-12 | Sndv Sprl | Betulonic acid derivatives |
WO2008063318A2 (fr) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Acide bétulinique, dérivés et analogues de celui-ci, et leurs utilisations |
CA2668452A1 (fr) | 2006-11-03 | 2008-05-15 | Panacos Pharmaceuticals, Inc. | Derives de triterpene etendus |
WO2008091532A1 (fr) | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Sels de l'acide 3-o-(3',3'-diméthylsuccinyl)bétulinique et leurs formes à l'état solide |
US8987212B2 (en) | 2007-08-07 | 2015-03-24 | Muhammed Majeed | Oleanoyl peptide composition and method of treating skin aging |
BRPI0820564A2 (pt) | 2007-11-13 | 2017-05-23 | Phoenix Biotechnology Inc | método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco |
AU2009237579C1 (en) | 2008-04-18 | 2016-05-12 | Reata Pharmaceuticals Holdings, LLC | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
WO2009129548A1 (fr) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Modulateurs d’inflammation antioxydants : dérivés d’acide oléanolique homologués c-17 |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
US20110224159A1 (en) | 2008-09-10 | 2011-09-15 | Universite du Quebec a Chicoutime | Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
WO2010053817A1 (fr) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Dérivés de l’acide bétulinique et leurs méthodes d’utilisation |
US8802727B2 (en) | 2009-07-14 | 2014-08-12 | Hetero Research Foundation, Hetero Drugs Limited | Pharmaceutically acceptable salts of betulinic acid derivatives |
CN101704872B (zh) | 2009-11-23 | 2012-06-27 | 张南 | 23-羟基白桦酸衍生物、其制备方法及应用 |
US8685469B2 (en) | 2009-11-30 | 2014-04-01 | University Of Kwazulu-Natal | In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives |
MX2012007977A (es) | 2010-01-11 | 2012-08-23 | Phoenix Biotechnology Inc | Metodo para tratar condiciones neurologicas con glicocidos cardiacos. |
US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
TWI386415B (zh) | 2010-02-02 | 2013-02-21 | Univ Kaohsiung Medical | 熊果酸衍生物及其醫藥組合物 |
TWI410431B (zh) | 2010-12-22 | 2013-10-01 | Ind Tech Res Inst | 齊敦果酸衍生物在製備預防或治療c型肝炎之藥物的用途 |
WO2012095705A1 (fr) | 2011-01-10 | 2012-07-19 | Hetero Research Foundation | Sels de qualité pharmaceutique de nouveaux dérivés de l'acide bétulinique |
DK2670764T3 (en) | 2011-01-31 | 2015-12-07 | Bristol Myers Squibb Co | C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS |
CN102558280B (zh) | 2011-11-18 | 2014-09-17 | 温州大学 | 一种30-卤代桦木酸的生产方法 |
JP6211527B2 (ja) | 2011-12-01 | 2017-10-11 | ハンジョウ ベンシェン ファーマシューティカル シーオー., エルティーディー.Hangzhou Bensheng Pharmaceutical Co., Ltd. | 2−置換オレアノール酸誘導体、その調製方法及びその用途 |
EP2787002B1 (fr) | 2011-12-01 | 2016-06-01 | Hangzhou Bensheng Pharmaceutical Co., Ltd. | Dérivés d'amidate d'acide oléanolique, procédés de préparation et utilisations correspondantes |
WO2013160810A2 (fr) | 2012-04-24 | 2013-10-31 | Hetero Research Foundation | Nouveaux dérivés d'acide bétulinique à titre d'inhibiteurs du vih |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
WO2014027777A2 (fr) | 2012-08-14 | 2014-02-20 | 한국콜마 주식회사 | Nouveau dérivé d'acide ursolique et son procédé de préparation |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
DK2892911T3 (en) | 2012-09-10 | 2017-10-23 | Reata Pharmaceuticals Inc | C17 heteroaryl derivatives of oleanolic acid and methods of use thereof |
UY35023A (es) | 2012-09-10 | 2014-03-31 | Reata Pharmaceuticals Inc | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso |
WO2014105926A1 (fr) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Nouveaux dérivés proline de l'acide bétulinique utilisés comme inhibiteurs du vih |
KR20150121712A (ko) | 2013-02-25 | 2015-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체 |
WO2015121168A1 (fr) * | 2014-02-12 | 2015-08-20 | Organobalance Gmbh | Souche de levure et procédé microbien de production de triterpènes et/ou triterpénoïdes pentacycliques |
US9920090B2 (en) | 2014-06-19 | 2018-03-20 | VIIV Healthcare UK (No.5) Limited | Betulinic acid derivatives with HIV maturation inhibitory activity |
US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
WO2016200672A1 (fr) * | 2015-06-08 | 2016-12-15 | Cutanea Life Sciences, Inc. | Composition thérapeutique |
-
2018
- 2018-07-16 IL IL285232A patent/IL285232B/en unknown
- 2018-07-16 MX MX2020002883A patent/MX2020002883A/es unknown
- 2018-07-16 EP EP18857189.7A patent/EP3681508A4/fr active Pending
- 2018-07-16 CA CA3075729A patent/CA3075729A1/fr active Pending
- 2018-07-16 RU RU2020113341A patent/RU2020113341A/ru unknown
- 2018-07-16 WO PCT/US2018/042226 patent/WO2019055119A1/fr unknown
- 2018-07-16 JP JP2020515911A patent/JP6820450B2/ja active Active
- 2018-07-16 KR KR1020207007406A patent/KR102295179B1/ko active IP Right Grant
- 2018-07-16 KR KR1020217026676A patent/KR20210107904A/ko active IP Right Grant
- 2018-07-16 AU AU2018334386A patent/AU2018334386B2/en active Active
-
2020
- 2020-03-09 IL IL273162A patent/IL273162B/en unknown
- 2020-06-25 AU AU2020204236A patent/AU2020204236B2/en active Active
-
2021
- 2021-01-04 JP JP2021000190A patent/JP7037673B2/ja active Active
-
2022
- 2022-03-04 JP JP2022033642A patent/JP2022075755A/ja active Pending
Non-Patent Citations (9)
Title |
---|
ASHBROOK ALISON W. ET AL: "Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection", MBIO, 24 May 2016 (2016-05-24), pages 1 - 14, XP055792193, Retrieved from the Internet <URL:https://mbio.asm.org/content/mbio/7/3/e00693-16.full.pdf> [retrieved on 20210401], DOI: 10.1128/mBio.00693-16 * |
AVCI OGUZHAN ET AL: "Nerium Oleander Distilati'nin Blue Tongue Virus Üzerine in vitro Etkisi In vitro Effect of Nerium Oleander Distillate on Blue Tongue Virus", AVKAE DERG, vol. 4, 1 January 2014 (2014-01-01), pages 14 - 18, XP055792186 * |
DWIVEDI VIVEK DHAR ET AL: "In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.", JOURNAL OF VECTOR BORNE DISEASES, vol. 53, no. 2, April 2016 (2016-04-01), pages 156 - 161, XP002802578, ISSN: 0972-9062 * |
FU XU ET AL: "Novel Chemical Ligands to Ebola Virus and Marburg Virus Nucleoproteins Identified by Combining Affinity Mass Spectrometry and Metabolomics Approaches", SCIENTIFIC REPORTS, vol. 6, no. 1, 12 July 2016 (2016-07-12), XP055792762, Retrieved from the Internet <URL:http://www.nature.com/articles/srep29680.pdf> DOI: 10.1038/srep29680 * |
GUPTA VIKAS ET AL: "PHYTOCHEMICAL AND PHARMACOLOGICAL POTENTIAL OF NERIUM OLEANDER: A REVIEW", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 1, no. 3, 1 January 2010 (2010-01-01), pages 21 - 27, XP055792176 * |
OGUZHAN AVCI ET AL: "Determination of in Vitro Antiviral Activity of Nerium Oleander Distillate against to Parainfluenza-3 Virus", ANIMAL AND VETERINARY SCIENCES, vol. 2, no. 5, 1 January 2014 (2014-01-01), pages 150 - 153, XP055762391, ISSN: 2328-5842, DOI: 10.11648/j.avs.20140205.14 * |
RAJBHANDARI M. ET AL: "Screening of Nepalese medicinal plants for antiviral activity", JOURNAL OF ETHNOPHARMACOLOGY, vol. 74, 1 January 2001 (2001-01-01), pages 251 - 255, XP055792595 * |
SINGH SHAILBALA ET AL: "Nerium oleanderderived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity", FITOTERAPIA, IDB HOLDING, MILAN, IT, vol. 84, 2 November 2012 (2012-11-02), pages 32 - 39, XP028968939, ISSN: 0367-326X, DOI: 10.1016/J.FITOTE.2012.10.017 * |
VAN KANEGAN MICHAEL J. ET AL: "Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 May 2016 (2016-05-01), XP055791907, Retrieved from the Internet <URL:http://www.nature.com/articles/srep25626> DOI: 10.1038/srep25626 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018334386A1 (en) | 2020-04-02 |
KR20200081356A (ko) | 2020-07-07 |
AU2020204236A1 (en) | 2020-07-16 |
JP2022075755A (ja) | 2022-05-18 |
RU2020113341A (ru) | 2021-10-15 |
JP2020534293A (ja) | 2020-11-26 |
EP3681508A1 (fr) | 2020-07-22 |
RU2020113341A3 (fr) | 2021-10-15 |
AU2018334386B2 (en) | 2021-11-04 |
CA3075729A1 (fr) | 2019-03-21 |
IL285232B (en) | 2022-07-01 |
KR20210107904A (ko) | 2021-09-01 |
IL273162B (en) | 2021-08-31 |
WO2019055119A1 (fr) | 2019-03-21 |
MX2020002883A (es) | 2020-10-05 |
IL273162A (en) | 2020-04-30 |
IL285232A (en) | 2021-09-30 |
AU2020204236B2 (en) | 2020-12-10 |
KR102295179B1 (ko) | 2021-08-30 |
JP2021063105A (ja) | 2021-04-22 |
JP6820450B2 (ja) | 2021-01-27 |
JP7037673B2 (ja) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3139954A4 (fr) | Méthodes et compositions pour traiter les infections par le virus de l'hépatite b | |
EP3684377A4 (fr) | Méthodes de traitement des infections de type hépatite b | |
EP3653630A4 (fr) | Composé thiamidinoamide-arylamide endocyclique et son utilisation dans le traitement de l'hépatite b | |
EP3512524A4 (fr) | Méthodes et compositions de traitement d'infections virales | |
EP3681508A4 (fr) | Méthode et composition pour le traitement d'une infection virale | |
EP3374350A4 (fr) | Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes | |
EP3442502A4 (fr) | Compositions, systèmes, kits et méthodes pour traiter une infection | |
EP3468593A4 (fr) | Compositions et procédés pour prévenir et traiter l'infection par le virus zika | |
EP3268010A4 (fr) | Compositions et méthodes de traitement d'une infection bactérienne | |
EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
EP3280422A4 (fr) | Compositions et méthodes de traitement d'une infection à vhb | |
EP3432891A4 (fr) | Méthodes de traitement et de prévention d'une infection à c. difficile | |
EP3317290A4 (fr) | Compositions et méthodes de traitement d'une infection virale | |
EP3166637A4 (fr) | Compositions et méthodes pour le traitement d'une infection par le virus de la dengue | |
EP3310382A4 (fr) | Compositions et méthodes pour traiter une infection virale | |
EP3250553A4 (fr) | Compositions et méthode d'inhibition d'une infection virale | |
EP3675813A4 (fr) | Méthode et composition destinées à prévenir et à traiter des infections virales | |
EP3352729A4 (fr) | Méthodes et compositions de traitement de la peau | |
ZA202202370B (en) | Compositions and methods for treating viral infections | |
EP3411367A4 (fr) | Compositions et méthodes de traitement d'infections bactériennes | |
EP3400008A4 (fr) | Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b | |
EP3534913A4 (fr) | Composition et méthode pour traiter des otites | |
EP3538108A4 (fr) | Méthodes de traitement et d'inhibition d'une infection par le virus ebola | |
EP3833387A4 (fr) | Compositions et procédés pour prévenir et traiter une infection virale | |
EP3768273A4 (fr) | Méthodes et compositions synergiques pour le traitement d'infections virales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031560000 Ipc: A61K0036240000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210416 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/24 20060101AFI20210409BHEP Ipc: A61K 31/56 20060101ALI20210409BHEP Ipc: A61K 31/7042 20060101ALI20210409BHEP Ipc: A61K 31/7048 20060101ALI20210409BHEP Ipc: A61P 31/12 20060101ALI20210409BHEP Ipc: A61P 31/14 20060101ALI20210409BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221004 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230921 |